In a bid to bolster its pipeline in diabetic retinopathy, Boehringer Ingelheim has entered into a licensing agreement with Surrozen in a deal worth up to US$599 M. Boehringer will be granted access to SZN-413, a bispecific antibody which acts on Fzd4-mediated Wnt signalling, developed using Surrozen’s SWAP™ technology platform to treat vascular-associated diseases. The asset is a welcome addition to Boehringer’s existing ophthalmology portfolio, which includes Phase I/IIdiabetic macular ischemia drug, BI 764524